RESCHEDULED: A Nationwide Trial for Smoldering Myeloma Patients
Drs. Cowan and Callander join the MGUS/Smoldering Myeloma community to share with us the nationwide ECOG/SWOG clinical trial, ECOG DETER SMM in which a Dara Rd regimen is being compared to Rd treatment across the nation for smoldering myeloma treatment.
As many of you, we remain hopeful with the amount of accelerated research being done in the smoldering and precursor myeloma fields.
We're excited to learn from them. Come with questions and learn how to enroll in this groundbreaking trial!
Audrey introduces the agenda of the event and our featured speakers Dr. Andrew J. Cowan and Dr. Natalie Callander.
Dr. Andrew J. Cowan and Dr. Natalie Callander share with us the nationwide ECOG/SWOG clinical trial.
Type your questions in the chat and we will answer them!
Audrey Burton-Bethke
Audrey joined the HealthTree Foundation as the Myeloma Community Program Director in 2020. While not knowing much about myeloma at the start, she has since worked hard to educate herself, empathize and learn from others' experiences. She loves this job. Audrey is passionate about serving others, loves learning, and enjoys a nice mug of hot chocolate no matter the weather.
Natalie Callander, MD
Dr. Natalie Callander is a faculty member in Division of Hematology, Medical Oncology and Palliative Care within the Department of Medicine. She is the Director of the UW Carbone Cancer Center Myeloma Clinical Program, Vice Chair of the NCCN Myeloma Committee, and Interim Director of Bone Marrow Transplant. She is a member of the NCI Myeloma Steering Committee and the ECOG Myeloma Committee She has received three UW Health Patient Experience Physician Champion Awards, named to Best Doctors in America list since 2004, a Madison Magazine Top Doctor three times, and received the Chuck Koval Award for Excellence in Myeloma presented by the Leukemia and Lymphoma Society.
Andrew J Cowan, MD
Dr. Andrew Cowan is a hematologist-oncologist who specializes in treating patients with multiple myeloma and other blood disorders. He leads clinical trials of new treatments for these diseases, including the use of engineered immune cells, combination strategies and genomics data. An expert in trial design, Dr. Cowan evaluates research proposals as a member of Fred Hutchinson Cancer Research Center's Scientific Review Committee.